Long-term follow-up of ETV6-RUNX1 ALL reveals that NCI risk, rather than secondary genetic abnormalities, is the key risk factor Leukemia (2013Leukemia ( ) 27, 2256Leukemia ( -2259 doi:10.1038/leu.2013 The ETV6-RUNX1 fusion gene is present in 25% of children diagnosed with B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) and is associated with an excellent outcome.
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Although ETV6-RUNX1-positive patients have a low relapse rate and good outcome after relapse, 2 averting relapse in this prevalent subgroup warrants investigation. Previous studies investigating risk factors in this subgroup have produced inconsistent results and have been hampered by small patient cohorts and/or treatment heterogeneity. [3] [4] [5] [6] ETV6-RUNX1 alone is insufficient to cause overt leukaemia and numerous cooperating mutations have been described. 7 Therefore, we sought to assess the prognostic relevance of secondary abnormalities targeting the ETV6 and RUNX1 genes as well as other abnormalities (for example, IKZF1 deletion) in a large cohort of patients.
A total of 368 children with ETV6-RUNX1 BCP-ALL were treated on MRC ALL97/99. 8 Both phases, ALL97 and ALL99, included a steroid and thiopurine randomization in induction and maintenance. In ALL97, patients received a 3-drug induction, 2/3 intensification blocks, central nervous system-directed treatment and continuing therapy for a total of 2 years. High-risk patients, identified by the Oxford Hazard Score or cytogenetics, were transferred to a more intensive protocol. In ALL99, children were stratified according to National Cancer Institute (NCI) risk to regimen A (standard risk (SR); o10 years and white cell count (WCC) o50 Â 10 9 /L) or regimen B (high risk (HR); others). Patients received a 3/4-drug induction (regimen A/B) and were deemed to be slow early responders (SERs) if the day 15/8 marrow contained X25% blasts. Patients who were SERs or had high-risk cytogenetics were transferred to regimen C. After induction, patients received consolidation, two interim maintenance blocks, two delayed intensification blocks and continuing therapy for a total of 2 (girls) or 3 (boys) years.
ETV6-RUNX1 was determined by fluorescent in situ hybridization (FISH) using the TEL-AML1 ES probe (Abbott Diagnostics, Maidenhead, UK) or by reverse transcription-PCR. 9 Secondary abnormalities affecting ETV6 or RUNX1 were determined in a representative cohort of 247 (67%) patients (Table 1) by FISH using two dual-colour breakapart probes: ETV6 (Dako Ltd, Ely, UK) and home-grown RUNX1 (RP11-272A03/RP11-396G11, Sanger Institute, UK). 9 Deletions of IKZF1, CDKN2A/B, PAX5, EBF1, ETV6, BTG1 and RB1 and the P2RY8-CRLF2 fusion were determined by multiplex ligation-dependent probe amplification (MLPA) in a representative cohort of 114 (31%) patients (Table 1 ) using the SALSA P335 kit (MRC Holland, Amsterdam, The Netherlands). 9 Event-free survival (EFS) and overall survival (OS) were calculated from the start of treatment to relapse/death and death, respectively. Patients without an event of interest were censored at the date of last contact. Survival estimates were calculated using the Kaplan-Meier method and compared using Cox proportional hazard regression models, which conformed to the proportional hazards assumption.
The clinical features and outcome of ETV6-RUNX1 patients by age group, WCC group, phase of trial, NCI risk group and key secondary abnormalities are detailed in Table 1 . The majority of ETV6-RUNX1 patients were NCI-SR and the proportion did not vary between ALL97 and ALL99: 135/175 (77%) versus 148/193 (77%), respectively. After a median follow-up time of 9.2 years, 47 (13%) relapses, 54 (15%) events and 20 (5%) deaths had been recorded (Table 1) . Only two patients failed to achieve a complete remission (CR), both of whom died within a month. Among the ALL99 cohort, nine (5%) patients were SER; two died in remission, two relapsed and five achieved sustained CR. In agreement with previous observations, [10] [11] [12] the temporal pattern of relapses was later than observed for other subtypes of ALL and 490% occurred after the end of treatment (EOT): 3 (6%) very early (o18 months after diagnosis), 4 (9%) early (418 months Accepted article preview online 2 May 2013; advance online publication, 21 May 2013 Letters to the Editor from diagnosis and o6 months after EOT) and 40 (85%) late relapses (46 months after EOT). However, in contrast to the Nordic Society of Paediatric Hematology and Oncology study, 10 which had a higher overall relapse rate, we observed a plateau at 8 years with no relapses among 229 patients followed up for 48 years.
NCI-HR patients had significantly greater risk of suffering an event and death compared to NCI-SR patients. Patients treated on ALL99 suffered fewer relapses compared with ALL97, which resulted in a borderline improved EFS but not OS. NCI-SR patients showed a significant improvement in EFS at 8 years in ALL99 compared with ALL97: 92% (95% confidence interval (CI) 86-96) versus 84% (76-89), hazard ratio 0.46 (95% CI 0.22-0.94), P ¼ 0.033. However, the benefit for the much smaller group of NCI-HR patients was more marginal: 78% (62-87) versus 73% (56-84), 0.81 (0.34-0.1.9), P ¼ 0.625. The difference in OS between NCI-HR and NCI-SR was similar in both the ALL97 and ALL99 phases: 85% (69-92) versus 97% (92-98), 5.45 (1.53-19.33), Po0.01 and 86% (72-93) versus 97% (92-98), 5.31 (1.50-18.85), P ¼ 0.01, respectively. Multivariate analysis confirmed that the adverse effect of NCI high-risk status was independent of trial phase and the adjusted HRs were not different (Table 1, Figure 1 ). Our results demonstrate the importance of NCI status in ETV6-RUNX1 patients. The observation that NCI and ETV6-RUNX1 status were independent risk factors is in agreement with other clinical study groups, 11, 13 although in contrast with St Jude Children's Research Hospital (SJCRH) who observed no effect of NCI risk group among 168 ETV6-RUNX1 patients. 12 However, as 450% of their patients were treated on Total XV, which had significantly superior results and ran between 2000 and 2007, their results are not directly comparable with our cohort who were treated between 1997 and 2001.
FISH and MLPA analyses of ETV6-RUNX1 patients revealed significant genetic heterogeneity, with 480% patients harbouring X1 of the tested abnormalities. Deletion of the non-rearranged ETV6 allele was the most prevalent secondary abnormality and was detected with equal frequency by FISH (164/245 (67%)) and MLPA (68/105 (65%)). Gain of the normal or derived chromosome 21 [der(21)t(12;21)] and deletions of CDKN2A/B, PAX5 and BTG1 were detected in 16-27% cases. Deletions of RB1, IKZF1 and EBF1 were rarer occurring in nine (8%), six (5%) and five (4%) patients, respectively. Only a single case harboured a P2RY8-CRLF2 fusion. None of the secondary abnormalities were associated with a distinctive patient profile with respect to sex, age, WCC or NCI risk group. Moreover, there was no evidence of outcome heterogeneity according to the presence of any of the secondary abnormalities investigated whether comparing patients with and without the abnormality in question or using the size of the subclone to investigate a trend effect (Table 1) . Although our results contradict several studies that have reported an association, [3] [4] [5] it is consistent with the largest and most recent study from Nordic Society of Paediatric Hematology and Oncology. 6 Therefore, while these abnormalities may have had genuine prognostic relevance on older protocols, there is no evidence that they need to be considered on future protocols. We are not aware of any studies that have examined the prognostic effect of IKZF1, CDKN2A/ B, PAX5, EBF1, BTG1 and RB1 deletions, specifically within an ETV6-RUNX1-positive cohort. Even though B25% patients harboured a deletion of CDKN2A/B, PAX5 or BTG1, none impacted significantly on outcome. The EFS for CDKN2A/B-deleted patients Abbreviations: CI, confidence interval; EFS, event-free survival; FISH, fluorescent in situ hybridization; MLPA, multiplex ligation-dependent probe amplification; NA, not applicable; NCI, National Cancer Institute; OS, overall survival; WCC, white cell count. Notes: (1) A total of 247/368 (67%) patients were screened by FISH for secondary abnormalities affecting ETV6 and RUNX1. The tested cohort was representative with respect to sex, age and survival. However, tested patients were more likely to have a WCC 450 Â 10 9 /l (22 vs 10%, Po0.01) and a greater portion of ALL99 patients were tested compared with ALL97 patients (70 vs 53%, Po0.01). A total of five FISH tests failed: ETV6 (n ¼ 2) and RUNX1 (n ¼ 3) probe; (2) A total of 114/368 (31%) patients were screened for gene micro-deletions by MLPA. The tested cohort was representative with respect to sex, age, WCC, phase of trial and survival. The copy number for PAX5 and BTG1 could not be called one case each; (3) hazard ratio from a multivariate model that included two variables, one for phase of trial and one for NCI risk group.
Letters to the Editor was low, but it should be noted that the result was based on only seven events and did not translate to an inferior OS. As expected, the incidence of IKZF1 deletions among ETV6-RUNX1 patients was lower than among childhood ALL generally. Given the strong association reported between IKZF1 deletions and poor prognosis, it is noteworthy that all six IKZF1-deleted patients have remained in first CR for 49.5 years. This observation supports previous data, indicating that the prognostic effect of IKZF1 deletions is pleiotropic. 14 In conclusion, ETV6-RUNX1 ALL patients have an excellent outcome when treated with contemporary regimens irrespective of the presence of additional genetic abnormalities. However, the adverse effects of NCI risk group based on age and WCC remain pertinent. A limitation of this study was the lack of data on minimal residual disease (MRD), which was not measured in this trial. MRD at various time points (for example, end of induction, end of consolidation, etc) has been shown to be predictive of outcome in ALL generally and among ETV6-RUNX1-positive cases. 15 However, the majority of ETV6-RUNX1 patients are MRD negative post induction, and the clinical utility of MRD is highly protocol specific. Therefore, the prognostic impact of static risk factors available at the time of diagnosis (for example, NCI risk status) is still useful in the clinical setting. Even though this study was large, the rarity of many secondary abnormalities restricted our ability to adequately assess their impact and this was compounded by a low relapse rate and the effect of NCI risk group. Therefore, it is unlikely that the genetic heterogeneity existing within this subtype will yield clinically relevant risk factors. 
